← All trials
NCT07107529
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2025
- Primary completion
- Apr 30, 2029
- Completion date
- Feb 28, 2034
- First posted
- Aug 6, 2025
- Last posted
- Aug 12, 2025
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- European Myeloma NetworkLead sponsor
- PETHEMA FoundationCollaborator
- University of SalamancaOfficial
- HOVON - Dutch Haemato-Oncology AssociationCollaborator
- University of OsloOfficial
- Janssen Pharmaceutica NVCollaborator
- Azienda Sanitaria Ospedaliera Molinette S. Giovanni BattistaOfficial
- Nordic Myeloma Study GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.